Predictive factors and survival outcome of conversion therapy for unresectable hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: Comparative analysis of conversion, partial response and complete response patients,Alimentary Pharmacology & Therapeutics

当前位置： X-MOL 学术 › Aliment. Pharm. Ther. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Predictive factors and survival outcome of conversion therapy for unresectable hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: Comparative analysis of conversion, partial response and complete response patients
Alimentary Pharmacology & Therapeutics ( IF 6.6 ) Pub Date : 2024-09-04 , DOI: 10.1111/apt.18237
Takeshi Hatanaka ₁ , Satoru Kakizaki _{2,

3} , Atsushi Hiraoka ₄ , Toshifumi Tada ₅ , Masashi Hirooka ₆ , Kazuya Kariyama ₇ , Joji Tani ₈ , Masanori Atsukawa ₉ , Koichi Takaguchi ₁₀ , Ei Itobayashi ₁₁ , Shinya Fukunishi ₁₂ , Kunihiko Tsuji ₁₃ , Toru Ishikawa ₁₄ , Kazuto Tajiri ₁₅ , Hidenori Toyoda ₁₆ , Chikara Ogawa ₁₇ , Hiroki Nishikawa ₁₈ , Takashi Nishimura ₁₂ , Kazuhito Kawata ₁₉ , Hisashi Kosaka ₂₀ , Atsushi Naganuma ₂₁ , Yutaka Yata ₂₂ , Hideko Ohama ₂₃ , Hidekatsu Kuroda ₂₄ , Tomomitsu Matono ₂₅ , Tomoko Aoki ₂₆ , Yuki Kanayama ₁ , Kazunari Tanaka ₁₃ , Fujimasa Tada ₄ , Kazuhiro Nouso ₇ , Asahiro Morishita ₈ , Akemi Tsutsui ₁₀ , Takuya Nagano ₁₀ , Norio Itokawa ₉ , Tomomi Okubo ₉ , Taeang Arai ₉ , Michitaka Imai ₁₄ , Shinichiro Nakamura ₅ , Hirayuki Enomoto ₁₂ , Masaki Kaibori ₂₀ , Yoichi Hiasa ₆ , Masatoshi Kudo ₂₆ , Takashi Kumada ₂₇ ,

Affiliation

Department of Gastroenterology, Gunma Saiseikai Maebashi Hospital, Maebashi, Japan.
Department of Clinical Research, NHO Takasaki General Medical Center, Takasaki, Japan.
Department of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, Maebashi, Japan.
Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.
Department of Internal Medicine, Japanese Red Cross Himeji Hospital, Himeji, Japan.
Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Matsuyama, Japan.
Department of Gastroenterology, Okayama City Hospital, Okayama, Japan.
Department of Gastroenterology and Neurology, Kagawa University, Kita-Gun, Takamatsu, Japan.
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
Department of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu, Japan.
Department of Gastroenterology, Asahi General Hospital, Asahi, Japan.
Department of Gastroenterology, Division of Hepatobiliary and Pancreatic Diseases, Hyogo Medical University, Nishinomiya, Japan.
Center of Gastroenterology, Teine Keijinkai Hospital, Sapporo, Japan.
Department of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan.
Department of Gastroenterology, Toyama University Hospital, Toyama, Japan.
Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Ogaki, Japan.
Department of Gastroenterology, Japanese Red Cross Takamatsu Hospital, Takamatsu, Japan.
Department of Gastroenterology, Osaka Medical and Pharmaceutical University, Osaka, Japan.
Hepatology Division, Department of Internal Medicine II, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Department of Surgery, Kansai Medical University, Hirakata, Japan.
Department of Gastroenterology, NHO Takasaki General Medical Center, Takasaki, Japan.
Department of Gastroenterology, Hanwa Memorial Hospital, Osaka, Japan.
Department of Gastroenterology, Takarazuka City Hospital, Takarazuka, Japan.
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Iwate Medical University, Iwate, Japan.
Department of Gastroenterology, Hyogo Prefectural Harima-Himeji General Medical Center, Himeji, Japan.
Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.
Gifu Kyoritsu University, Ogaki, Japan.

This study aims to investigate the predictive factors for conversion therapy in patients with unresectable hepatocellular carcinoma (uHCC) and to evaluate the prognosis of conversion cases by comparing them with partial response (PR) and complete response (CR) cases.

中文翻译：